DEC 23, 2019 8:08 AM PST

FDA Approves New Schizophrenic Drug

WRITTEN BY: Nouran Amin

The US Food and Drug Administration (FDA) has approved an atypical antipsychotic Caplyta (lumateperone; Intra-Cellular Therapies) for the treating schizophrenia in adult patients.

Confirmation to market the drug comes from two double-blinded studies that evaluated Caplyta in schizophrenic patients for 28 days. Results were affirming and showed the taking 42mg of Caplyta daily was enough to reduce schizophrenic symptoms from baseline to Day 28.

Learn more about schizophrenia:

Like every other drug, safety is a priority Caplyta is no exception. The drug comes with a boxed warning for increased mortality rates among elderly patients receiving the medication for dementia-related psychosis. The most persist side-effects was sedation and dry mouth.

“Schizophrenia is a complex disease that severely impacts patients and their families,” said Jeffrey A. Lieberman, MD, Lawrence C. Kolb Professor and Chairman of Psychiatry, Columbia University, College of Physicians and Surgeons and Director, New York State Psychiatric Institute. “Effective treatment provided in a timely fashion can be game-changing for people living with schizophrenia. The efficacy and safety profile of Caplyta approved by the FDA, offers healthcare providers an important new option for treating people living with schizophrenia.”

How does Caplyta work? The exact mechanism remains a mystery but it is generally believed to work its magic by antagonizing the activity of particular serotonin receptors known the 5-HT2A and the postsynaptic activity of the central dopamine D2 receptors.

Caplyat will be marketed in 42mg capsules provided in 30-count boxes.

Source: IntraCellularTherapies

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 02, 2022
Cell & Molecular Biology
Pipette Matchmaker: Tip Compatibility Like Never Before
MAY 02, 2022
Pipette Matchmaker: Tip Compatibility Like Never Before
Article Written by John Winsor All lab workers have to do it, shifting countless stacks of indiscernible boxes to f ...
APR 21, 2022
Cannabis Sciences
One of the most lucrative skillsets in cannabis
APR 21, 2022
One of the most lucrative skillsets in cannabis
For anyone looking for a well-compensated, in demand job in the cannabis industry, you can't go wrong with becoming an e ...
MAY 05, 2022
Drug Discovery & Development
Insulin Nasal Spray Improves Cognitive Outcome for Diabetes Patients
MAY 05, 2022
Insulin Nasal Spray Improves Cognitive Outcome for Diabetes Patients
Diabetes is an increasingly common condition that affects at least 1 in 10 U.S adults. Millions more have prediabetes an ...
MAY 12, 2022
Drug Discovery & Development
Gut Bacteria Composition Predicts Resposnse to Statins
MAY 12, 2022
Gut Bacteria Composition Predicts Resposnse to Statins
The composition of the gut microbiome is predictive of patient responses to statins. The corresponding study was publish ...
JUN 06, 2022
Drug Discovery & Development
Express Media Service Q&A with Sheng Li, PhD., FUJIFILM Irvine Scientific
JUN 06, 2022
Express Media Service Q&A with Sheng Li, PhD., FUJIFILM Irvine Scientific
FUJIFILM Irvine Scientific sat down with Sheng Li, PhD, Program Manager, to speak about our rapid service for small-scal ...
JUN 02, 2022
Drug Discovery & Development
NSAIDs Can Have Different, Unexpected Effects on People. Why?
JUN 02, 2022
NSAIDs Can Have Different, Unexpected Effects on People. Why?
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common types of drugs used to treat pain and inflammat ...
Loading Comments...